These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37599866)

  • 1. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.
    Sanchez-Gistau V; Moreno MJ; Gómez-Lus S; Sicras-Mainar A; Crespo-Facorro B
    Front Psychiatry; 2023; 14():1207307. PubMed ID: 37599866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
    Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
    J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
    Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
    Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia.
    Such P; Bøg M; Kabra MS; Jørgensen KT; de Jong-Laird AC
    Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34592798
    [No Abstract]   [Full Text] [Related]  

  • 6. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.
    Wilson M; Gutierrez B; Offord SJ; Blanchette CM; Eramo A; Earnshaw S; Kamat SA
    Drugs Context; 2016; 5():212273. PubMed ID: 27114739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study.
    Waters HC; Touya M; Wee SN; Ng M; Thadani S; Surendran S; Rentería M; Rush AJ; Patel R; Sarkar J; Fitzgerald HM; Han X
    Curr Med Res Opin; 2023 Feb; 39(2):299-306. PubMed ID: 36380678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
    Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
    CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Curr Med Res Opin; 2018 Jan; 34(1):41-47. PubMed ID: 29057674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
    Olivares JM; González-Pinto A; Páramo M;
    Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics.
    Lafeuille MH; Tandon N; Tiggelaar S; Kamstra R; Lefebvre P; Kim E; Yue Y; Joshi K
    Drugs Real World Outcomes; 2018 Mar; 5(1):81-90. PubMed ID: 29363022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
    Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.